Esther12
Senior Member (Voting Rights)
I wonder why Hilda Bastian appears to have been replaced?
Hopefully she's okay.
I wonder why Hilda Bastian appears to have been replaced?
Yes.
Any questions you want me to ask?
Are you attending the talk?
I agree that it might be better not to criticize D. Bishop directly and to name particular trials on ME only as examples as a general problem that all trials on therapist-delivered treatments bring with them if they don't apply any objective outcomes and at the same time cannot be blinded.Probably best to only ask something prompted by the meeting? Maybe about the role patients should be able to play raising standards for the research that affects their lives, but the danger of prejudice, stigma and (particularly in the UK) snobbery getting in the way? Could mention the Bastian concern: "Instead of responsiveness to criticism, some – not all – researchers have put massive effort into discrediting the whole community and rallying other researchers to their defense. It’s been a collective ad hominem attack." https://blogs.plos.org/absolutely-m...-the-me-cfs-exercise-dispute-matters-so-much/
edit: Mentioning that you were attending partly in the hope of thanking Bastian could make you seem less threatening? Maybe I'm over-thinking things.
Interesting. I'm reading Crawley's bit, most of it is BS, but noted this nugget: "The abuse stopped". That's definitely not what she's been saying since and certainly not what was claimed at the information tribunal or her fake TEDx letter.Are you attending the talk?
I don't know. Bishop co-wrote that really annoying Nature piece that indicates she had no real understanding of the problems around PACE:
http://statmodeling.stat.columbia.edu/wp-content/uploads/2016/02/Lewandowsky-Bishop-2016-Nature.pdf
She had also co-arranged this conference where criticism of PACE and SMILE were presented as exogenous threats to science:
https://s3-eu-west-1.amazonaws.com/pfigshare-u-files/3663015/RS_scienceandsociety_September_2015.pdf
She then failed to address the fact that SMILE was clearly 'prospectively' registered after it had started, and after data from trial participants had led to the primary outcome being changed: http://www.virology.ws/2018/06/25/trial-by-error-my-exchange-with-professor-bishop/
You could challenge her on something related to that, but I expect it could easily go wrong and be presented as abusive harassment.
Maybe better to ask Chambers something? - I think that he expressed some vague concerns about the refusal to release PACE data although always gave the impression that he didn't want to mess with Wessely & co.
Probably best to only ask something prompted by the meeting? Maybe about the role patients should be able to play raising standards for the research that affects their lives, but the danger of prejudice, stigma and (particularly in the UK) snobbery getting in the way? Could mention the Bastian concern: "Instead of responsiveness to criticism, some – not all – researchers have put massive effort into discrediting the whole community and rallying other researchers to their defense. It’s been a collective ad hominem attack." https://blogs.plos.org/absolutely-m...-the-me-cfs-exercise-dispute-matters-so-much/
edit: Mentioning that you were attending partly in the hope of thanking Bastian could make you seem less threatening? Maybe I'm over-thinking things.
tbh, I think that my instincts are often to adversarial for UK academia, so any suggestions I make are likely to lead to you being viewed as an extremist! Hope it's interesting for you.
Literally lying out of the gate with it being controlled. It's in the name that it was not a controlled trial.The PACE (Pacing, graded Activity and Cognitive behaviour therapy: a randomised Evaluation) trial was a randomised controlled trail
How would a single patient withdrawing consent cause a 4 months delay? Is that a BS explanation or are they that bad?As a result of concerns about confidentiality, one participant withdrew their consent for us to use their data, some two years after leaving the trial; this led to us having to restart the analysis, which caused a four month delay in publication of the main results.
Yeah, that's totally why they did not release the minutes without a FOI. Totally. I believe that.our patient representatives asked us not to release minutes of meetings for fear of harassment
A large number of Freedom of Information Act requests seeking information on all aspects of the trial were received since the main results were published in 2011.
Some requests were complied with [...] All appeals were rejected
Selective compliance is literally the opposite of transparency.Our deliberate policy, to help allay concerns about the trial, was to be as transparent as possible
Hi, what are you reading here from Crawley? Are you maybe conflating Crawley and Chalder and reading Chalder's testimony from the tribunal?I'm reading Crawley's bit
Hi, what are you reading here from Crawley? Are you maybe conflating Crawley and Chalder and reading Chalder's testimony from the tribunal?
The fact that I was doing a trial investigating an alternative intervention and had criticised the XMRV story, made a few people very angry indeed. Over the next 12 months, I was sent aggressive and threatening emails, dealt with lots of Freedom of Information requests and was reported to: the General Medical Council (GMC; our regulator); the University of Bristol (my employer); the National Society of Protection of Children and the National Research Ethics Service.
I was defamed in the accusations made to the regulatory authorities and in an article in the Church Times. A YouTube clip was made from the talk I gave to the patient support group dubbed with different words. The complaints were quickly dismissed and the University and patient support groups were supportive. The police got involved and helped me realise the complaints came from what they called “extremists”, that this was a co-ordinated campaign and that nothing had come from my patient group. They recommended that I and other CFS researchers went public and I told my story through newspapers, TV, radio and scientific journals. The abuse stopped. I have received one apology three years later.
This one: https://s3-eu-west-1.amazonaws.com/pfigshare-u-files/3663015/RS_scienceandsociety_September_2015.pdf.Hi, what are you reading here from Crawley? Are you maybe conflating Crawley and Chalder and reading Chalder's testimony from the tribunal?
I have no idea what she's talking about with XMRV. It was created in the lab? What?
I have no idea what she's talking about with XMRV. It was created in the lab? What?
And always strawmanning: claiming people were certain that this was it, this was the cause, insistent on it, screaming from the rooftops that this was guaranteed to be it. Why do they have to caricature behavior and hyperbolize that much?
Hi, what are you reading here from Crawley? Are you maybe conflating Crawley and Chalder and reading Chalder's testimony from the tribunal?
No it's new to me. I'm going to read them.Had you not read this, David?
thanks I hadn't seen this beforeIt's Crawley:
thanks I hadn't seen this before
In a sense 'created in the lab' is exactly right. It seems that a stray mouse retrovirus got into lab cell cultures and underwent a change in its DNA to become a new variant that infected cells in ME and prostate cancer studies.
The lab cell culture story is a nice little soundbite but it is like the patient anonymity story for the PACE trial data - it might be true but it was late in coming and has some very big holes in it. I have no particular feeling that XMRV is associated with ME. I hope not because it would be very difficult to treat, but the "science" of the controversy was abysmal and unlikely.
The lab cell culture story is a nice little soundbite but it is like the patient anonymity story for the PACE trial data - it might be true but it was late in coming and has some very big holes in it. I have no particular feeling that XMRV is associated with ME. I hope not because it would be very difficult to treat, but the "science" of the controversy was abysmal and unlikely.
Another of the four withdrew her consent retroactively and forbade the researchers from using her data in the published results. “I wasn’t given the option of being informed, quite honestly,” she said, requesting anonymity because of ongoing legal matters related to her illness. “I felt quite pissed off and betrayed. I felt like they lied by omission.”
Q: What protection should there be for information relating to the internal deliberations of public bodies? For how long after a decision does such information remain sensitive? Should different protections apply to different kinds of information that are currently protected by sections 35 and 36? - What protection should there be for information relating to the internal deliberations of public bodies? For how long after a decision does such information remain sensitive? Should different protections apply to different kinds of information that are currently protected by sections 35 and 36?
A: It is an important principle of science that internal deliberations should be undertaken in a "safe space", allowing for freely expressed arguments for and against decisions made in planning and implementing a scientific study. It is equally important that such decisions, and the reasons for making them, are recorded formally and accurately, so that these documents can be used as source references used at the time of writing up and publishing research. This would not be possible, or would be very limited, if such minutes of such meetings were known to be liable to public release. This would have a "chilling" effect on open discussion This is particularly the case in Medicine where the principle of patient involvement in research is so valuable - individual patients and patient organisations are vulnerable to abuse and harassment if their names were to be made public as part of such minutes. Making such data exempt from the Act would protect scientific work in controversial subjects within and outside of medicine. Please refer to Information Tribunal decision notice Appeal No: EA/2013/0019, where Judge Hughes outlines these arguments in more detail, in an appeal regarding a medical research trial that I led (see answers to question 6).
Q: Is the burden imposed on public authorities under the Act justified by the public interest in the public’s right to know? Or are controls needed to reduce the burden of FoI on public authorities? If controls are justified, should these be targeted at the kinds of requests which impose a disproportionate burden on public authorities? Which kinds of requests do impose a disproportionate burden? - Is the burden imposed on public authorities under the Act justified by the public interest in the public’s right to know? Or are controls needed to reduce the burden of FoI on public authorities? If controls are justified, should these be targeted at the kinds of requests which impose a disproportionate burden on public authorities? Which kinds of requests do impose a disproportionate burden?
A:
I am the principal investigator (PI) of the PACE trial, the main findings of which were published in the Lancet medical journal in 2011 (White PD et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. The Lancet 2011;377:823-36. doi:10.1016/S0140-6736(11)60096-2). I write here in my personal capacity.
The PACE trial is a trial of four treatments for patients suffering from chronic fatigue syndrome (CFS), which is sometimes called myalgic encephalomyelitis (ME). CFS is a controversial condition, and attracts a strong patient activist voice. This group has used the FoI Act many times since this main paper was published, asking for all sorts of data, from the minutes of all meetings overseeing the trial to all of the patient data collected. See the following for a description of activism (http://www.bmj.com/content/342/bmj.d3780)
The administration of these requests has caused a very significant burden on the University's FOIA manager, the University's academic department of law, and myself as PI. I have had to spend a considerable amount of time addressing the requests, advising colleagues, collating the views of my research colleagues at other universities, and writing witness statements for the various appeals (internal, ICO and IT). This means that my further research into the causes and treatments of this debilitating and misunderstood illness has been delayed. Paradoxically, the time taken up in this has delayed publication of the papers that contain some of the very data that have been requested.
Perhaps most damaging of all have been requests by two trial ex-participants to "destroy" all their data collected on them during the trial because of their concern that the data will not be held securely and confidentially, something we promised them to do as part of their giving informed consent. The first such request was received after we had finished all trial data collection and had started the main analysis. After some months of trying to obtain advice on what to do, we were advised to destroy this ex-participant's data, which we did (and which took some time to do due to the complexity of the data), but this meant that we had to restart the analysis, which caused several month's delay in publishing the main results paper in 2011. This paper was important since it showed that there were two treatments for this condition which were safe and moderately effective. It is estimated that some 250,000 people suffer from CFS in the UK.
Section 22a of the Act is insufficient protection for science into controversial subjects, and requires that the research is on-going, so is irrelevant to completed research. We need science in the UK to be protected or it will continue to be damaged as this trial has been (other examples include climate change science, and research into the health effects of tobacco). Exempting Universities from the FOIA would achieve that. Exempting scientific research data produced by Universities and other higher educational institutes might be a workable alternative.